AusperBio to Present Chronic Hepatitis B Treatment Data at AASLD
AusperBio will present long-term follow-up data for its AHB-137 treatment for chronic hepatitis B in two late-breaking oral presentations at the AASLD Liver Meeting. The data concerns a novel therapeutic approach.
AusperBio Therapeutics is set to present research findings on its novel chronic hepatitis B treatment, AHB-137, in two late-breaking oral presentations at the American Association for the Study of Liver Diseases (AASLD) annual meeting, The Liver Meeting®. These presentations will feature long-term follow-up data assessing the drug's efficacy and safety.
The presentations are scheduled to take place in San Francisco on October 7, 2026. AHB-137 is a potential new therapeutic agent developed by AusperBio for the treatment of chronic hepatitis B virus infection. The company aims to provide alternative options to current therapies, which do not always achieve viral eradication.
Chronic hepatitis B remains a significant global health challenge, capable of leading to severe liver conditions such as cirrhosis and liver cancer. The development of new and improved treatment modalities is crucial for enhancing patient outcomes.
AusperBio's presentations at AASLD will offer industry researchers and clinicians an opportunity to evaluate the long-term impact of AHB-137. The company anticipates receiving valuable insights that will inform future clinical development.